

AMENDMENT

In the Claims:

Please cancel claims 1-21, without prejudice.

Please amend claims 24, 26, and 36 to read as follows:

Sub
B2
A1

24. (Amended) The composition of claim 22, wherein the anticancer agent is selected from the group consisting of methotrexate, cisplatin, prednisone, hydroxyprogesterone, medroxyprogesterone acetate, megestrol acetate, diethylstilbestrol, testosterone propionate, fluoxymesterone, vinblastine, vincristine, vindesine, daunorubicin, doxorubicin, hydroxyurea, procarbazine, aminoglutethimide, mechlorethamine, cyclophosphamide, melphalan, uracil mustard, chlorambucil, busulfan, carmustine, lomustine, dacarbazine (DTIC, dimethyltriazenomideazolecarboxamide), procarbozine, 5-fluorouracil, cytarabine, cytosine arabinoside, 6-mercaptopurine, tamoxifen, paclitaxel, etoposide, vinorelbine, gemcitabine, leuprolide, flutamide, goserelin acetate, thioguanine, and their derivatives mixtures thereof.

A2

26. (Amended) The composition of claim 22, wherein the nanocrystalline or poorly crystalline calcium phosphate cement comprises a calcium phosphate selected from the group consisting of amorphous calcium phosphate, poorly crystalline apatitic (PCA) calcium phosphates, dicalcium phosphates, such as dicalcium phosphate dihydrate (DCPD) and dicalcium phosphate anhydrous (DCPA), tricalcium phosphates (TCP),

monetite, monocalcium phosphate monohydrate (MCPM), heptacalcium phosphate,

A2 calcium pyrophosphate, calcium metaphosphate, octacalcium phosphates (OCP),

hydroxyapatites (HA).

36. (Amended) The composition of claim 22, wherein a therapeutically effective

A3 amount of anticancer agent is released from the composition for a time greater than two weeks.
